We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
The Pittsburgh Life Sciences Greenhouse Invests $100,000 for Achieving Improved Diagnosis of Disease
News

The Pittsburgh Life Sciences Greenhouse Invests $100,000 for Achieving Improved Diagnosis of Disease

The Pittsburgh Life Sciences Greenhouse Invests $100,000 for Achieving Improved Diagnosis of Disease
News

The Pittsburgh Life Sciences Greenhouse Invests $100,000 for Achieving Improved Diagnosis of Disease

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "The Pittsburgh Life Sciences Greenhouse Invests $100,000 for Achieving Improved Diagnosis of Disease"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Pittsburgh Life Sciences Greenhouse (PLSG), the private/public partnership putting the region's life sciences industry on a fast track for growth, has announced that PLSG has invested $100,000 in RedPath Integrated Pathology, Inc.

The company provides specialized cancer diagnostic testing that integrates traditional pathology practice with molecular genetic analysis to improve the diagnosis of disease.

"RedPath's patented platform approach, PathFinderTG™ has made tremendous advances in the diagnosis of cancer," said Doros Platika, M.D., the President and Chief Executive Officer of the PLSG.

"The company has struck the right balance between pathology, molecular analysis and the information sciences to successfully apply genomic advances in the clinical setting." Dr. Platika, continued,

"In two short years, RedPath has gained real traction in the marketplace as evidenced by an ever-increasing number of marquis clients and steady increases in revenues."

RedPath's PathFinderTG is effective at resolving uncertain diagnoses by answering important questions from pathologists and clinicians when standard testing is inconclusive.

It has been clinically validated for use in a wide range of specialties, including cancers of the gastrointestinal tract, pancreas, and brain, and it improves patient outcomes by reducing the potential for inappropriate, incomplete or unnecessary treatment.

"RedPath's role in changing tissue analysis from a static to dynamic process has earned us a position within that small but growing class of molecular-based companies that are pushing healthcare closer to personalized medicine," said Mary Del Brady, RedPath's President and Chief Executive Officer.

"With the kind of support we have gotten from the PLSG, we are even more confident that we will be able to achieve a series of key goals that will help us to maintain our leadership position."

Advertisement